Skip To Content

 

Insights

Recent updates

 

Sharing perspectives leads to greater understanding and fuels innovation

Check out our latest updates:

September 20, 2023 · Clinical Team
Zavzpret – indicated for the acute treatment of migraine with or without aura in adults – is now available as a 10 mg nasal spray device. Read more...
September 15, 2023 · Clinical Team
According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more...
September 01, 2023 · Clinical Team
Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more...
August 16, 2023 · Public Policy & Regulatory Affairs Team
Brief postings include proposed updates to California DWC medical treatment guidelines and the Michigan Supreme Court rules on retro-applicability of certain auto no-fault fee schedule provisions. Read more...
August 11, 2023 · Clinical Team
FDA approves additional over-the-counter naloxone products Read more...
July 26, 2023 · Public Policy & Regulatory Affairs Team
Brief updates include changes to work comp evaluating physician fees in New Jersey; updates to Tennessee work comp inpatient hospital fee schedule, medical payment regulations, and medical fee schedule rules; and adopted New York PBM regulations. Read more...
July 18, 2023 · Clinical Team
The 2Q 2023 Brand-Generic Pipeline update Read more...
July 06, 2023 · Clinical Team
Extended-release Brixadi has been approved by the FDA for subcutaneous injection in patients recovering from Opioid Use Disorder as part of their treatment plan. Read more...
<< Previous      Next >>
Page 4 of 5